<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03713502</url>
  </required_header>
  <id_info>
    <org_study_id>TMA2017GSF-1965</org_study_id>
    <nct_id>NCT03713502</nct_id>
  </id_info>
  <brief_title>Enteropathy and Diabetes in HIV Patients</brief_title>
  <acronym>REEHAD</acronym>
  <official_title>The Role of Environmental Enteropathy on HIV Associated Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute for Medical Research, Tanzania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>London School of Hygiene and Tropical Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Queen Mary University of London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute for Medical Research, Tanzania</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Emerging data suggest that HIV-infected people have disproportionately higher risk of
      diabetes than HIV-uninfected people. Multiple factors may contribute to elevated diabetes
      risk including increased prevalence of conventional non-communicable diseases (NCDs) risk
      factors, use of some antiretroviral drugs regimens, and inflammation and immune activation
      secondary to environmental- and HIV-enteropathy. To date, enteropathy has been little studied
      in relation to HIV and diabetes in Sub-Saharan Africa. Enteropathy leads to systemic
      inflammation which may in turn result in insulin resistance and may reduce secretion of
      incretins, the gut hormones which stimulate synthesis and secretion of insulin. Both
      mechanisms could potentially result in higher diabetes risk in HIV patients. This study
      investigates the hypothesis that among HIV-infected patients environmental enteropathy
      increase the risk of diabetes. The findings of this study will provide information which
      could be used as a basis for developing clinical trials to address different aspects of
      environmental enteropathy in order to reduce the burden of diabetes among HIV-infected
      populations
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will investigate if enteropathy is associated with higher risk of diabetes in HIV
      patients using a cross-sectional study design. To implement it cost-efficiently,
      investigators will nest it to an ongoing cohort study which investigates risk factors for
      diabetes and other chronic diseases among HIV patients in Tanzania (the CICADA study)
      (NCT03106480).

      The CICADA study recruited 1947 participants during 2016/2017. These will be followed- up
      during 2017/2018 and 2018/2019 by which point it is expected that about 1550 participants
      will be retained in the cohort. Data collection for the current study will coincide with the
      final CICADA study follow-up. Data on demography, socio-economic status, conventional
      non-communicable disease risk factors, HIV and TB status, antiretroviral therapy use history,
      anthropometry, body composition, lipid profile, CD4 count, C-reactive protein, alpha-1-acid
      glycoprotein, insulin, and diabetes status will be retrieved from CICADA study. Data on gut
      enteropathy biomarkers i.e plasma citrulline, GLP-1, glucagon like peptide-2 (GLP-2),
      glucose-dependent insulinotropic polypeptide (GIP), fecal myeloperoxidase (MPO), neopterin,
      and alpha-1-antitrypsin, intestinal permeability (by 4-sugar test), lipopolysaccharide
      binding protein, tumor necrosis factor-Î± receptor, interleukin 6, and fecal elastase (as an
      indicator of pancreatic function) will be collected solely for this study to investigate the
      study hypothesis.

      Data will be entered in Cspro and managed and analysed in STATA. Both linear and logistic
      regression will be used to assess the associations between exposure variables (markers of
      enteropathy) and outcome (diabetes). In addition, causal inference techniques will be used to
      investigate associations between enteropathy biomarkers and diabetes.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2019</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of diabetes</measure>
    <time_frame>January 2019 to December 2019</time_frame>
    <description>Investigators will determine prevalence of diabetes among participants with enteropathy and those without enteropathy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Prevalence of pre-diabetes</measure>
    <time_frame>January 2019 to December 2019</time_frame>
    <description>Investigators will determine prevalence of pre-diabetes among participants with enteropathy and those without enteropathy</description>
  </primary_outcome>
  <enrollment type="Anticipated">1947</enrollment>
  <condition>Diabetes</condition>
  <condition>Environmental Enteropathy</condition>
  <condition>HIV</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, stool and urine samples collected for analysis of enteropathy biomarkers
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Participants will be recruited from HIV-infected patients attending antiretroviral therapy
        (ART) clinics in Mwanza (Tanzania) as well as from the general population (those who meet
        the inclusion criteria).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria: Participants who were recruited in CICADA study (NCT03106480) during
        2016/2017 and meet the following criteria:

          -  Aged 18 years or above

          -  HIV-infected

          -  HIV-uninfected

          -  Resident of Mwanza region

          -  Consent to take part in this study

        Exclusion Criteria:

          -  None
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr George PrayGod, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute for Medical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr Daniel Faurholt-Jepsen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Copenhagen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Prof Suzanne Filteau, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>London School of Hygiene and Tropical Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>George PrayGod, MD, PhD</last_name>
    <phone>+255 28 2503012</phone>
    <phone_ext>220</phone_ext>
    <email>gpraygod@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bazil Kavishe, MD, MSc</last_name>
    <phone>+255 28 2503012</phone>
    <phone_ext>218</phone_ext>
    <email>basilbkavishe@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>NIMR Research Clinic</name>
      <address>
        <city>Mwanza</city>
        <state>Mwanza Region</state>
        <country>Tanzania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Tanzania</country>
  </location_countries>
  <reference>
    <citation>Brown TT, Cole SR, Li X, Kingsley LA, Palella FJ, Riddler SA, Visscher BR, Margolick JB, Dobs AS. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med. 2005 May 23;165(10):1179-84. Erratum in: Arch Intern Med. 2005 Nov 28;165(21):2541.</citation>
    <PMID>15911733</PMID>
  </reference>
  <reference>
    <citation>Maganga E, Smart LR, Kalluvya S, Kataraihya JB, Saleh AM, Obeid L, Downs JA, Fitzgerald DW, Peck RN. Glucose Metabolism Disorders, HIV and Antiretroviral Therapy among Tanzanian Adults. PLoS One. 2015 Aug 19;10(8):e0134410. doi: 10.1371/journal.pone.0134410. eCollection 2015.</citation>
    <PMID>26287742</PMID>
  </reference>
  <reference>
    <citation>PrayGod G, Changalucha J, Kapiga S, Peck R, Todd J, Filteau S. Dysglycemia associations with adipose tissue among HIV-infected patients after 2 years of antiretroviral therapy in Mwanza: a follow-up cross-sectional study. BMC Infect Dis. 2017 Jan 30;17(1):103. doi: 10.1186/s12879-017-2209-z.</citation>
    <PMID>28137307</PMID>
  </reference>
  <reference>
    <citation>Prendergast A, Kelly P. Enteropathies in the developing world: neglected effects on global health. Am J Trop Med Hyg. 2012 May;86(5):756-63. doi: 10.4269/ajtmh.2012.11-0743. Review.</citation>
    <PMID>22556071</PMID>
  </reference>
  <reference>
    <citation>Nazli A, Chan O, Dobson-Belaire WN, Ouellet M, Tremblay MJ, Gray-Owen SD, Arsenault AL, Kaushic C. Exposure to HIV-1 directly impairs mucosal epithelial barrier integrity allowing microbial translocation. PLoS Pathog. 2010 Apr 8;6(4):e1000852. doi: 10.1371/journal.ppat.1000852.</citation>
    <PMID>20386714</PMID>
  </reference>
  <reference>
    <citation>Klatt NR, Funderburg NT, Brenchley JM. Microbial translocation, immune activation, and HIV disease. Trends Microbiol. 2013 Jan;21(1):6-13. doi: 10.1016/j.tim.2012.09.001. Epub 2012 Oct 11. Review.</citation>
    <PMID>23062765</PMID>
  </reference>
  <reference>
    <citation>Boden G. Free fatty acids, insulin resistance, and type 2 diabetes mellitus. Proc Assoc Am Physicians. 1999 May-Jun;111(3):241-8. Review.</citation>
    <PMID>10354364</PMID>
  </reference>
  <reference>
    <citation>James WP, Coore HG. Persistent impairment of insulin secretion and glucose tolerance after malnutrition. Am J Clin Nutr. 1970 Apr;23(4):386-9.</citation>
    <PMID>5441174</PMID>
  </reference>
  <reference>
    <citation>Indulekha K, Anjana RM, Surendar J, Mohan V. Association of visceral and subcutaneous fat with glucose intolerance, insulin resistance, adipocytokines and inflammatory markers in Asian Indians (CURES-113). Clin Biochem. 2011 Mar;44(4):281-7. doi: 10.1016/j.clinbiochem.2010.12.015. Epub 2011 Jan 8.</citation>
    <PMID>21219897</PMID>
  </reference>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>October 17, 2018</study_first_submitted>
  <study_first_submitted_qc>October 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2018</study_first_posted>
  <last_update_submitted>December 17, 2018</last_update_submitted>
  <last_update_submitted_qc>December 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Institute for Medical Research, Tanzania</investigator_affiliation>
    <investigator_full_name>Dr George PrayGod</investigator_full_name>
    <investigator_title>Principal Research Scientist</investigator_title>
  </responsible_party>
  <keyword>Pre-diabetes</keyword>
  <keyword>Diabetes</keyword>
  <keyword>HIV</keyword>
  <keyword>Enteropathy</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Microbial translocation</keyword>
  <keyword>Endotoxin translocation</keyword>
  <keyword>Insulin resistance</keyword>
  <keyword>Visceral obesity</keyword>
  <keyword>Incretin hormones</keyword>
  <keyword>GLP-1</keyword>
  <keyword>GLP-2</keyword>
  <keyword>GIP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

